US Pharma MarketingKyowa Kirin secures FDA approval for Crysvita dosing update
Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH. Following the update, healthcare providers can increase both the dose and frequency of Crysvita for XLH patients after treatment. The recombinant, fully human monoclonal IgG1 antibody targets fibroblast growth factor 23 in XLH. Credit: Michele Ursi / Shutterstock.com. Kyowa Kirin has received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing information for Crysvita (burosumab-twza), introducing a new option for adults with X-linked hypophosphataemia (XLH). Affecting adults and…
Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.
Source: Pharmaceutical Technology